Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-845-7291
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$43.13 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Tilray (NASDAQ:TLRY) Frequently Asked Questions
What is Tilray's stock symbol?
Tilray trades on the NASDAQ under the ticker symbol "TLRY."
How were Tilray's earnings last quarter?
Tilray Inc (NASDAQ:TLRY) posted its earnings results on Tuesday, August, 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.09. The company had revenue of $45.90 million for the quarter, compared to analysts' expectations of $40.25 million. Tilray had a negative return on equity of 37.64% and a negative net margin of 121.73%. The company's revenue was up 373.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. View Tilray's Earnings History.
When is Tilray's next earnings date?
What price target have analysts set for TLRY?
17 equities research analysts have issued twelve-month target prices for Tilray's stock. Their predictions range from $25.00 to $81.10. On average, they anticipate Tilray's stock price to reach $52.88 in the next twelve months. This suggests a possible upside of 147.4% from the stock's current price. View Analyst Price Targets for Tilray.
What is the consensus analysts' recommendation for Tilray?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tilray.
What are Wall Street analysts saying about Tilray stock?
Here are some recent quotes from research analysts about Tilray stock:
- 1. According to Zacks Investment Research, "Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. " (10/16/2019)
- 2. Jefferies Financial Group Inc analysts commented, "We initiate at Underperform, PT $61. With arguably inferior positioning in parts of its business vs. certain peers (questionable Canada rec approach, less impressive US optionality, too much value credited to ABI/ABG), we struggle to justify the current valuation. We appreciate it is well placed in medical but future value here will be driven by IP for which little visibility near term. Its share structure also raises risk of increased volatility." (3/8/2019)
Has Tilray been receiving favorable news coverage?
Media stories about TLRY stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tilray earned a news impact score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Tilray.
Are investors shorting Tilray?
Tilray saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 8,100,000 shares, an increase of 8.3% from the August 30th total of 7,480,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is presently 4.9 days. Currently, 36.5% of the shares of the stock are sold short. View Tilray's Current Options Chain.
Who are some of Tilray's key competitors?
Some companies that are related to Tilray include Canopy Growth (CGC), STADA Arzneimittel (STDAF), Aurora Cannabis (ACB), Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Rivers (RIV), Sundial Growers (SNDL), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN) and FitLife Brands (FTLF).
What other stocks do shareholders of Tilray own?
Who are Tilray's key executives?
Tilray's management team includes the folowing people:
- Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
- Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
- Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
- Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board
When did Tilray IPO?
(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.
Who are Tilray's major shareholders?
Tilray's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Commerzbank Aktiengesellschaft FI (0.05%), Exane Derivatives (0.01%) and Wealthcare Advisory Partners LLC (0.00%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr and Mark Castaneda. View Institutional Ownership Trends for Tilray.
Which major investors are selling Tilray stock?
TLRY stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr and Mark Castaneda. View Insider Buying and Selling for Tilray.
Which major investors are buying Tilray stock?
TLRY stock was bought by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI and Wealthcare Advisory Partners LLC. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy and Edward Wood Pastorius Jr. View Insider Buying and Selling for Tilray.
How do I buy shares of Tilray?
Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tilray's stock price today?
One share of TLRY stock can currently be purchased for approximately $21.37.
How big of a company is Tilray?
Tilray has a market capitalization of $2.09 billion and generates $43.13 million in revenue each year. The company earns $-67,720,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. View Additional Information About Tilray.
What is Tilray's official website?
How can I contact Tilray?
Tilray's mailing address is 1100 Maughan Road, Nanaimo A1, V9X IJ2. The company can be reached via phone at 844-845-7291.
MarketBeat Community Rating for Tilray (NASDAQ TLRY)
MarketBeat's community ratings are surveys of what our community members think about Tilray and other stocks. Vote "Outperform" if you believe TLRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
